Cost-Effectiveness Analysis of Pembrolizumab for First-Line Treatment in Patients with Persistent, Recurrent, and Metastatic Cervical Cancer in the United States: Results from the Final Analysis of Trial

Cost-Effectiveness of Pembrolizumab Plus Chemotherapy, with or without Bevacizumab for the First-Line Treatment of Pd-L1-Positive Patients with Persistent, Recurrent, or Metastatic Cervical Cancer in France

Can We Speak to GPT to Inform Health Technology Assessments?

Unraveling Modeling Challenges in the Economic Evaluations of Gene Therapies: A Global Review

From Submission to Reimbursement: Navigating the COVID-19 Ripple Effect on Therapy Access in Canada

Methodological Insights on Indirect Treatment Comparisons for Ulcerative Colitis Therapies in NICE Submissions

Unleashing the Power of Social Media Listening: A Promising Tool for Patient-Focused Research

Q-TWiST Analysis Is Back in the Game in Oncology Clinical Trial Analysis: A Recent Trend
